iShares U.S. Pharmaceuticals ETF (IHE)
|Ex-Dividend Date||Sep 24, 2021|
|Day's Range||184.87 - 187.21|
|Inception Date||May 1, 2006|
The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
Top 10 Holdings77.02% of assets
|Johnson & Johnson||JNJ||22.42%|
|Elanco Animal Health||ELAN||4.53%|
|Sep 24, 2021||$0.832||Sep 30, 2021|
|Jun 10, 2021||$0.72063||Jun 16, 2021|
|Mar 25, 2021||$0.63484||Mar 31, 2021|
|Dec 14, 2020||$0.5261||Dec 18, 2020|
|Sep 23, 2020||$0.70888||Sep 29, 2020|
|Jun 15, 2020||$0.31386||Jun 19, 2020|
The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Robust results led to solid trading in pharma ETFs in a month.
Healthcare stocks and sector-related exchange traded funds found support from a strong start to the earnings season after UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) provided a much...
Despite robust results, pharma ETFs have been trending downward in a month.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.